Loading patent…
AssigneeXalud Therapeutics, Inc.
InventorsJayson Michael Rieger, David Glover, Howard Rutman, Stephen Collins, Diem Nguyen
Estimating the term…
The present disclosure describes a dosing regimen of an IL-10F129S expression construct for treating an inflammatory joint disease (e.g., osteoarthritis) in a subject. Methods are provided for treating an inflammatory joint disease in a subject by injecting a first dose and second dose of a composition comprising an IL-10F129S expression construct into an inflamed joint of the subject according to a dosing regimen wherein the two doses of the expression construct are administered to a subject approximately 150-360 days apart. The present disclosure also provides kits comprising a first and second dose of an IL-10F129S expression construct. The kits may be useful for treating an inflammatory joint disease in a subject.
A method for treating an inflammatory joint disease in a subject, the method comprising:
A method for treating an inflammatory joint disease in a subject, comprising:
Use of a composition comprising an IL-10F129S expression construct for the treatment of an inflammatory joint disease, wherein the composition is for administration in a first dose comprising 150 μg to 450 μg of the IL-10F129S expression construct, and wherein the composition is for administration in a second dose comprising 150 μg to 450 μg of the IL-10F129S expression construct 150-360 days after the first dose.
A kit comprising a first dose and a second dose of an IL-10F129S expression construct, wherein the first dose comprises 150 μg to 450 μg of the expression construct, and wherein the second dose comprises 150 μg to 450 μg of the expression construct;
Dependencies are inferred from the claim text.